Skip to main content
SpringerLink
Log in

Association of Cornell product with metabolic syndrome in middle-aged people in China

  • Original Article
  • Published:
International Journal of Diabetes in Developing Countries Aims and scope Submit manuscript

Abstract

Background

Metabolic syndrome (MS) has attracted much attention worldwide for its harmful effects. Although the Cornell product (CP) and Sokolow-Lyon (SL) voltage are independent and strong risk factors of cardiovascular disease, their associations with MS and the relative strength of these associations are unknown. Therefore, we studied these aspects in a community of middle-aged people.

Methods

A total of 1112 community residents aged 40–65 years, among which 169 had IDF (2005)–defined MS (MS group) and 943 did not have MS (NMS group), underwent electrocardiography (ECG) at baseline. A questionnaire survey, physical measurements, laboratory biochemical assessments, urine test, ECG, body fat analysis, and abdominal MRI examination were performed subsequently. Fifty-eight participants had developed MS (new-onset MS group) at the follow-up, while 472 residents had not developed MS over the next year (MS-free group). We compared the CP and SL voltage between these two groups.

Results

In the overall analysis, CP values were higher in the MS group than in the NMS group (p < 0.05), but SL voltage values were not significantly different (p > 0.05). In the gender-stratified multivariate analysis, CP was significantly different in the male and female populations (p < 0.05), but SL voltage was only different in the male population (p = 0.042). After removing hypertension from MS and NMS groups, there was still significant difference in CP value (< 0.05). Thus, CP showed a more pronounced influence. The new-onset MS group showed significantly higher CP values and the changes in CP values than did the MS-free group at baseline and follow-up (p < 0.05), but the changes in SL values were not significant (p > 0.05).

Conclusions

CP values differed significantly between the MS and NMS groups. The new-onset MS group showed higher baseline CP values. Thus, CP is more advantageous than SL voltage in presaging the incidence of MS-related cardiovascular risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Arnlov J, Lind L, Zethelius B, et al. Several factors associated with the insulin resistance syndrome are predictors of left ventricular systolic dysfunction in a male population after 20 years of follow-up. Am Heart J. 2001;142(4):720–4.

    Article  CAS  PubMed  Google Scholar 

  2. Chinali M, Devereux RB, Howard BV, Roman MJ, Bella JN, Liu JE, et al. Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (the Strong Heart Study). Am J Cardiol. 2004;93(1):40–4.

    Article  PubMed  Google Scholar 

  3. Ingelsson E, Arnlov J, Lind L, Sundstrom J. Metabolic syndrome and risk for heart failure in middle-aged men. Heart. 2006;92(10):1409–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Otaki Y, Takahashi H, Watanabe T, et al. Electrocardiographic left ventricular hypertrophy Cornell product is a feasible predictor of cardiac prognosis in patients with chronic heart failure. Clin Res Cardiol. 2014;103(4). Germany):275–84.

    Article  PubMed  Google Scholar 

  5. Ishikawa J, Ishikawa S, Kario K. Levels of Cornell voltage and Cornell product for predicting cardiovascular and stroke mortality and morbidity in the general Japanese population. Circ J. 2014;78(2):465–75.

    Article  PubMed  Google Scholar 

  6. Santhanakrishnan R, Wang N, Larson MG, Magnani JW, Vasan RS, Wang TJ, et al. Racial differences in electrocardiographic characteristics and prognostic significance in Whites versus Asians. J Am Heart Assoc. 2016;5(3):e002956.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356–9.

    Article  PubMed  Google Scholar 

  8. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159–219.

    Article  PubMed  Google Scholar 

  9. Rigato M, Boscari F, Marcuzzo G, et al. Development of metabolic syndrome and electrocardiographic features of left ventricular hypertrophy in middle-aged working subjects. J Endocrinol Investig. 2013;36(11):1027–31.

    CAS  Google Scholar 

  10. Holmang A, Yoshida N, Jennische E, Waldenstrom A, Bjorntorp P. The effects of hyperinsulinaemia on myocardial mass, blood pressure regulation and central haemodynamics in rats. Eur J Clin Investig. 1996;26(11):973–8.

    Article  CAS  Google Scholar 

  11. Bell DS. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care. 2003;26(8):2433–41.

    Article  PubMed  Google Scholar 

  12. Okin PM, Jern S, Devereux RB, Kjeldsen SE, Dahlof B. Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients : the losartan intervention for endpoint (LIFE) reduction in hypertension study. Hypertension. 2000;35:1 Pt 1): 13–8.

    Article  PubMed  Google Scholar 

  13. Sosner P, Cabasson S, Hulin-Delmotte C, Saulnier PJ, Gand E, Torremocha F, et al. Effect of Cornell product and other ECG left ventricular hypertrophy criteria on various cardiovascular endpoints in type 2 diabetic patients. Int J Cardiol. 2014;175(1):193–5.

    Article  PubMed  Google Scholar 

  14. Park JK, Shin JH, Kim SH, Lim YH, Kim KS, Kim SG, et al. A comparison of Cornell and Sokolow-Lyon electrocardiographic criteria for left ventricular hypertrophy in Korean patients. Korean Circ J. 2012;42(9):606–13.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Ishikawa J, Yamanaka Y, Toba A, Watanabe S, Harada K. Gender-adjustment and cutoff values of Cornell product in hypertensive Japanese patients. Int Heart J. 2017;58(6):933–8.

    Article  PubMed  Google Scholar 

  16. Devereux RB, Bella J, Boman K, Gerdts E, Nieminen MS, Rokkedal J, et al. Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Blood Press. 2001;10(2):74–82.

    Article  CAS  PubMed  Google Scholar 

  17. Sundstrom J, Lind L, Arnlov J, Zethelius B, Andren B, Lithell HO. Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men. Circulation. 2001;103(19):2346–51.

    Article  CAS  PubMed  Google Scholar 

  18. Rodriguez-Padial L, Bacharova L. Electrical remodeling in left ventricular hypertrophy-is there a unifying hypothesis for the variety of electrocardiographic criteria for the diagnosis of left ventricular hypertrophy. J Electrocardiol. 2012;45(5):494–7.

    Article  PubMed  Google Scholar 

  19. Pewsner D, Juni P, Egger M, Battaglia M, Sundstrom J, Bachmann LM. Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: systematic review. BMJ. 2007;335(7622):711.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Okin PM, Devereux RB, Harris KE, et al. In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study. Hypertension. 2007;50(5):984–90.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This work was supported by the National Key Technology R&D Program of China (No. 2009BAI80B02).

Author information

Authors and Affiliations

  1. Department of Endocrinology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, No. 3 Qingchun East Road, Hangzhou, 310016, Zhejiang, China

    Feng Xuefang, Sun Shuiya & Zhou Jiaqiang

  2. Department of General, Ci Xi People’s Hospital, Cixi, Zhejiang, China

    Feng Xuefang & Chen Xiaoying

  3. Ci Xi Center for Disease Control and Prevention, Cixi, Zhejiang, China

    Yu Jianfeng

Authors
  1. Feng Xuefang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yu Jianfeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sun Shuiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chen Xiaoying
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhou Jiaqiang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhou Jiaqiang.

Ethics declarations

The study was approved by the ethics committee of Sir Run Run Shaw Hospital.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xuefang, F., Jianfeng, Y., Shuiya, S. et al. Association of Cornell product with metabolic syndrome in middle-aged people in China. Int J Diabetes Dev Ctries 40, 185–190 (2020). https://doi.org/10.1007/s13410-019-00771-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13410-019-00771-w

Keywords

Search

Navigation